Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Wloclawek

21 clinical trials in Wloclawek, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Wloclawek at a glance
21
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

21 trials in Wloclawek

Open in trial search

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Colitis ulcerative+1

Recruiting

Long-term safety study of tulisokibart in adults with Crohn's disease or ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Study on BI 3032950 for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 3032950
  • Sponsor:Boehringer Ingelheim International GmbH

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Not recruiting

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Wloclawek

What the registry says about research in the country

01 Gastrointestinal Research

Innovative clinical trials focusing on inflammatory bowel diseases, particularly exploring new therapeutic approaches for ulcerative colitis and Crohn's disease. Multiple studies are evaluating novel medications and combination therapies for patients with moderate to severe conditions.

  • Ulcerative Colitis Treatment Studies
  • Crohn's Disease Management
  • Novel Therapeutic Combinations

Research includes assessment of medications like guselkumab and innovative oral formulations for improving patient outcomes.

02 Cardiovascular Studies

Groundbreaking research in cardiovascular disease management, including studies on preventing heart attacks and strokes. Trials are investigating new approaches for acute coronary syndrome and heart failure treatment.

  • Atherosclerotic Disease Prevention
  • Heart Failure Management
  • Antiplatelet Therapy Optimization

Studies focus on improving outcomes for patients with established cardiovascular conditions through innovative therapeutic strategies.

03 Clinical Outcomes Research

Comprehensive evaluation of treatment efficacy across various therapeutic areas, with emphasis on measuring clinical remission and patient response rates. Studies incorporate both short-term and long-term assessment periods.

  • Treatment Response Assessment
  • Safety Monitoring
  • Comparative Effectiveness Studies

Research protocols include detailed monitoring of patient outcomes and safety parameters across multiple therapeutic interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.